Continuing Education Event – Addressing the Triple Threat of Stimulants, Opioids and Covid-19 – Webinar – 5/4/2021

Lethality, availability and use of stimulants have greatly increased in the US in past years. The Centers for Disease Control and Prevention has reported that overdose deaths have more than tripled for cocaine and increased nearly five-fold for methamphetamine since 2012. A UN report shows Colombian coca production more than tripled between 2012 and 2016 while over the same period, prices fell 23%, and purity increased nearly 20%. The threat from meth includes a new wave of purer methamphetamine and cocaine, coming directly from Mexico, not “backyard cookeries, houses or sheds.” Some areas of the country have seen staggering increases in meth seizures as high as 1600%. USA Today reports that “people addicted to opiates hear others talk about a new high, cheap and easy to get and safer than fentanyl. Meth is that alternative.” With more than 130 deaths every day in this country attributed to opioid overdose, there is understandable – and much appreciated – attention to this issue. A significant increase in overdose death rates from synthetic opioids such as fentanyl make it very clear that we must continue to address the threat from the opioids in this country.

These two major drug problems, and our field, are now impacted by an unprecedented 3rd threat in this country, that of the Covid-19 pandemic. At the time of this writing, just over 1.5 million Americans have tested positive for Covid-19 and 93,705 people have died of this disease. Individuals struggling with substance use disorder (SUD) or those in recovery may find COVID-19 and the non-medical impacts of COVID-19 more difficult than the general population. Individuals with SUD are more vulnerable to getting COVID-19 and more likely to have severe cases when they do get it. There has been an increase in substance use for those with a period of remission, particularly those with 3-12 months in recovery. Social isolation has led to increases in depression, anxiety, domestic violence, and other mental health disorders. With this “triple threat” of opioids, stimulants, and Covid-19, we need to rethink how we deliver assess, support and deliver treatment to those with SUD. This is particularly true for cocaine and amphetamines as there is no “gold standard” of treatment and no effect medications available.

• Describe the current problem with stimulants in the US
• Describe the 3 Waves of the opioid epidemic
• Explore special vulnerabilities to COVID-19 for those with DUD
• Understand how we can support the field during the current Covid-19 pandemic
• Understand what to look for in treatment of opioid and stimulant disorders.

Recovery Centers of America has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7002. Programs that do not qualify for NBCC credit are clearly identified. Recovery Centers of America is solely responsible for all aspects of the programs. This course qualifies for 1 credit hour.
Deni Carise, Ph.D.

Chief Scientific Officer
Deni Carise, Ph.D. is a Clinical Psychologist and part of the recovery community for over 30 years. She is currently Chief Scientific Officer of Recovery Centers of America (RCA) and Adjunct Assistant Professor at University of Pennsylvania. RCA is dedicated to creating neighborhood-based treatment and recovery campuses that include detoxification, residential, partial hospital, intensive and traditional outpatient, and family services, all available on one campus. Beginning in March 2016, they opened 6 such campuses, 2 in MA and MD, and 1 each in PA and NJ, multiple outpatient programs and one opioid treatment program. Their goal is to get 1 million Americans into meaningful recovery.
Deni has held similar positions at CRC Health Group, providing behavioral health services to more than 42,000 men, women and teens every day at more than140 programs in 33 states and Phoenix House, a nonprofit substance abuse treatment provider with over 100 programs in 10 states where Dr Carise developed national standards for clinical care, Clinical Toolkits for over 30 evidence-based practices, and helped usher in a new era of care to position the company to successfully address changes secondary to healthcare reform. Dr Carise was also Chief Clinical Advisor for Sierra Tucson, a premier facility treating substance abuse, pain, mood, eating and trauma disorders.


May 04 2021


12:00 pm - 1:00 pm

More Info

Enroll Today


Continuing Education
Enroll Today
Call Now! 1-800-RECOVERY


Treatment Advisor
Standing By, 24/7